Inhibrx announces impressive results for INBRX-106 in treating HPV-positive head and neck cancer, achieving a high response rate and significant progression-free survival metrics.

Johnson & Johnson shares pivotal data from their OrigAMI-4 study, highlighting RYBREVANT FASPRO™'s strong effectiveness against advanced head and neck squamous cell carcinoma.

Join the Head and Neck Cancer Foundation's free oral cancer screening events from April 13-17 for awareness and early detection across 19 states.

The Head and Neck Cancer Drugs Market is set for significant growth, driven by increased immunotherapy adoption and innovation in targeted treatments.

Johnson & Johnson reports a 45% response rate for subcutaneous amivantamab in head and neck cancer, with significant durability in patient responses.

GORTEC has declared significant results from the NIVOPOSTOP GORTEC 2018-01 study, showing Nivolumab's effectiveness in enhancing disease-free survival for high-risk head and neck cancer patients.

GORTEC announces significant findings from their Phase 3 trial on nivolumab for head and neck cancer, marking a breakthrough in treatment options.

GORTEC has announced successful results from its Phase 3 trial, NIVOPOSTOP GORTEC 2018-01, showcasing improved outcomes for head and neck cancer patients.